In our preclinical models including APG-2449 alone or in concert with other agents, this multikinase inhibitor demonstrated anticancer activity in various types of solid tumors, including NSCLC carrying ALK, ROS1, or EGFR mutations and ovarian cancer expressing FAK alterations and elevated CD44 protein expression. This evidence concerns the gene PTK2 and ovarian carcinoma.